Showing results (571-580 of 727) with videos related to

Sort By:
Pageof 73
The Journal of Biological Chemistry|May 11, 2012
Characterization of Caulobacter crescentus FtsZ protein using dynamic light scatteringSen Hou, Stefan A Wieczorek, Tomasz S Kaminski, et al.
Nature Communications|May 5, 2023
Paired immunoglobulin-like receptor B is an entry receptor for mammalian orthoreovirusPengcheng Shang, Joshua D Simpson, Gwen M Taylor, et al.
Nature Communications|April 22, 2025
SAMD9 senses cytosolic double-stranded nucleic acids in epithelial and mesenchymal cells to induce antiviral immunityGaopeng Hou, Wandy Beatty, Lili Ren, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 27, 2021
Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIsE Felip, A T Shaw, A Bearz, et al.
Lung Cancer (Auckland, N.Z.)|February 4, 2020
Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 StudiesShirish Gadgeel, Alice T Shaw, Fabrice Barlesi, et al.
JTO Clinical and Research Reports|July 11, 2022
A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on CrizotinibJaime L Schneider, Alona Muzikansky, Jessica J Lin, et al.
ACS Catalysis|April 15, 2026
Enantioselective Synthesis of Complex Carbocycles by C-H Insertion of Aryl/Aryl CarbenesJose M Ruiz, Dylan R Turner, Mingchun Gao, et al.
Cancer Chemotherapy and Pharmacology|February 6, 2013
Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trialJ L Welsh, B A Wagner, T J van't Erve, et al.
Genes & Development|March 21, 2007
Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesisAlice T Shaw, Alexander Meissner, James A Dowdle, et al.
ESMO Open|July 19, 2018
Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancerSai-Hong Ignatius Ou, Mark A Socinski, Shirish Gadgeel, et al.
Pageof 73